Updated
Reviewed
Aug. 01, 2019
Appendix B: Panel Roster and Financial Disclosures
Invasive Mycoses
| Member | Financial Disclosure | ||
|---|---|---|---|
| Company | Relationship | ||
| Ampel, Neil | University of Arizona | None | N/A |
| Boulware, David | University of Minnesota | Appili Therapeutics | Research Support |
| bioMerieux | Speaker’s Bureau | ||
| Gilead | Research Support | ||
| Hamill, Richard | Baylor College of Medicine | None | N/A |
| Kauffman, Carol* | University of Michigan and VA Ann Arbor Healthcare System | Veterans Education and Research Association of Michigan | Research Support |
| Miceli, Marisa | University of Michigan | Astellas | Advisory Board, Consultant, Research Support |
| SCYNEXIS | Consultant, Research Support | ||
| Pappas, Peter | University of Alabama at Birmingham | Astellas Pharma | Research Support |
| Cidara Therapeutics | Advisory Board | ||
| Merck | Research Support | ||
| SCYNEXIS | Advisory Board, Research Support | ||
| Perfect, John | Duke University | Amplyx Pharmaceuticals | Advisory Board, Research Support |
| Astellas | Advisory Board, Research Support | ||
| Matinas BioPharma Holdings, Inc | Advisory Board | ||
| Merck | Advisory Board | ||
| Minnetronix | Research Support | ||
| Mycovia Pharmaceuticals | Advisory Board | ||
| Pfizer | Research Support | ||
| Toyama | Research Support | ||
| * Group lead Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019. |
|||
Download Guidelines
- Section OnlyPDF (337.79 KB)
- Full GuidelinePDF (3.78 MB)
- Tables OnlyPDF (481.21 KB)